Guidance on Reporting and Reviewing Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others: Draft - October 11, 2005
Rockville, MD: Office for Human Research Protections, 2005 October 11: 25 p. [Online]. Accessed: http://www.hhs.gov/ohrp/requests/aerg.pdf [2007 March 10]
Showing items related by title, author, creator and subject.
Guidance for Industry: Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events: Draft Guidance Center for Biologics Evaluation and Research [CBER] (United States) (2005-08)
Draft Guidance for Industry on Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events; Availability United States. Food and Drug Administration [FDA] (2005-08-23)
Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials Unknown author (National Institutes of Health [NIH] (United States), 1999-06-11)